Stock Market Reviews

Read and share opinions on JUNS (Jupiter Neurosciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
  Nov 5, 2025
• Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
  Oct 27, 2025
• Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
  Sep 15, 2025
• Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
  Aug 26, 2025
• Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
  Aug 19, 2025
• Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
  Aug 11, 2025
• Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science
  Jul 23, 2025
• Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
  Jul 10, 2025
• Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
  Jun 30, 2025
• Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
  Jun 27, 2025
• Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
  Jun 23, 2025
• Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
  Jun 9, 2025
• Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
  Apr 8, 2025
• Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Mar 7, 2025
• Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
  Mar 4, 2025
• Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
  Feb 4, 2025
• Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
  Feb 3, 2025
• Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
  Jan 30, 2025
• Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials
  Jan 13, 2025
• Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
  Dec 4, 2024